DelveInsight’s, “Chronic Obstructive Pulmonary Disease Pipeline Insight, 2022,” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Chronic Obstructive Pulmonary Disease Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Obstructive Pulmonary Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Chronic Obstructive Pulmonary Disease Pipeline Report
Recent Developmental Activities in the Chronic Obstructive Pulmonary Disease Pipeline Report
Request a sample and discover the recent advances in Chronic Obstructive Pulmonary Disease Medication @ Chronic Obstructive Pulmonary Disease Clinical Trials Analysis
Chronic Obstructive Pulmonary Disease Overview
Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable disease. It is a poorly reversible lung disease characterized by persistent and progressive airflow limitation caused by an enhanced chronic inflammatory response in the airways and the lungs due to noxious particles or gases. Excessive Smoking is the leading risk factor for COPD. In addition, occupational and environmental exposure to chemical fumes, dust, and other lung irritants accounts for 10–20% of cases. People with a history of severe lung infections in childhood are more likely to develop COPD. Also, α1 antitrypsin deficiency is a rare cause of COPD. The most common symptom of COPD is chronic and progressive dyspnea. Production of cough and sputum is present in up to 30% patient population. The symptoms may vary from day to day and may develop airflow limitation by many years. Diagnosis for COPD is primarily clinical. Most of the patients are diagnosed by primary care physicians. Screening is recommended with the occurrence and long-term persistence of symptoms such as chronic cough, excessive sputum production, and dyspnea, especially when these symptoms are accompanied by a history of cigarette smoking or regular exposure to occupational or environmental pollutants or toxins. Spirometry (used to assess the integrated mechanical function of the lung, chest wall, respiratory muscles, and airways) is used to confirm the diagnosis of COPD in suspected cases. Currently, there is no cure for COPD; however, treatment can help slow disease progression rate and symptoms.
Chronic Obstructive Pulmonary Disease Emerging Drugs
Chronic Obstructive Pulmonary Disease Pipeline Therapeutic Analysis
There are approx. 70+ key companies which are developing the therapies for Chronic Obstructive Pulmonary Disease. The companies which have their Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca.
Learn more about the emerging Chronic Obstructive Pulmonary Disease pipeline therapies @ Chronic Obstructive Pulmonary Disease Treatment Landscape
DelveInsight’s Chronic Obstructive Pulmonary Disease Pipeline report covers around 50+ products under different phases of clinical development like
Scope of the Chronic Obstructive Pulmonary Disease Pipeline Report
Table of Content
Key Questions
Current Treatment Scenario and Emerging Therapies:
Got queries? For more information related to the Chronic Obstructive Pulmonary Disease Pipeline outlook report @ Chronic Obstructive Pulmonary Disease Pipeline Drugs
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/